Difference between revisions of "CNS carcinoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "#b3e2cd" to "#f2f3f4") |
||
(15 intermediate revisions by 3 users not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | {{#lst: | + | {{#lst:Editorial board transclusions|neuro}} |
− | + | This page has regimens and guidelines that are not specific to any one type of cancer. For disease-specific regimens and guidelines, please go to the following pages: | |
*[[Breast cancer, CNS metastases]] | *[[Breast cancer, CNS metastases]] | ||
*[[Non-small cell lung cancer, CNS metastases]] | *[[Non-small cell lung cancer, CNS metastases]] | ||
− | + | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 15: | Line 15: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
− | ==[ | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *'''2022:''' Schiff et al. [https://doi.org/10.1200/jco.22.00333 Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline] | + | ==[https://www.asco.org/ ASCO]== |
+ | *'''2022:''' Schiff et al. [https://doi.org/10.1200/jco.22.00333 Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline] [https://pubmed.ncbi.nlm.nih.gov/35561283 PubMed] | ||
==ASCO/SNO/ASTRO== | ==ASCO/SNO/ASTRO== | ||
− | *'''2021:''' Vogelbaum et al. [https://doi.org/10.1200/JCO.21.02314 Treatment for Brain Metastases] | + | *'''2021:''' Vogelbaum et al. [https://doi.org/10.1200/JCO.21.02314 Treatment for Brain Metastases] [https://pubmed.ncbi.nlm.nih.gov/34932393 PubMed] |
==EANO/ESMO== | ==EANO/ESMO== | ||
− | *'''2021:''' Le Rhun et al. [https://doi.org/10.1016/j.annonc.2021.07.016 EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours] | + | *'''2021:''' Le Rhun et al. [https://doi.org/10.1016/j.annonc.2021.07.016 EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours] [https://pubmed.ncbi.nlm.nih.gov/34364998 PubMed] |
− | *'''2017:''' Le Rhun et al. [https://www.esmo.org/Guidelines/Neuro-Oncology/EANO-ESMO-Leptomeningeal-Metastasis-Clinical-Practice-Guidelines EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours] | + | *'''2017:''' Le Rhun et al. [https://www.esmo.org/Guidelines/Neuro-Oncology/EANO-ESMO-Leptomeningeal-Metastasis-Clinical-Practice-Guidelines EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours] [https://pubmed.ncbi.nlm.nih.gov/28881917 PubMed] |
− | ==[https:// | + | ==ISRS== |
− | *[https://www.nccn.org/ | + | *'''2022:''' Grishcuk et al. [https://doi.org/10.1016/j.prro.2022.10.013 ISRS Technical Guidelines for Stereotactic Radiosurgery: Treatment of Small Brain Metastases (≤1 cm in Diameter)] [https://pubmed.ncbi.nlm.nih.gov/36435388/ PubMed] |
+ | *'''2018:''' Chao et al. [https://doi.org/10.1093/neuros/nyx522 Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline] [https://pubmed.ncbi.nlm.nih.gov/29126142/ PubMed] | ||
+ | |||
+ | ==NCCN== | ||
+ | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425 NCCN Guidelines - Central Nervous System Cancers].'' | ||
=All lines of therapy= | =All lines of therapy= | ||
Line 44: | Line 49: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Radiotherapy==== | ====Radiotherapy==== | ||
− | *[[External_beam_radiotherapy|Whole-brain irradiation]] | + | *[[External_beam_radiotherapy|Whole-brain irradiation]] 250 cGy fractions x 15 (total dose: 3750 cGy) |
'''One course''' | '''One course''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''RTOG 0118:''' Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. [https://doi.org/10.1016/j.ijrobp.2007.09.016 link to original article] ''' | + | #'''RTOG 0118:''' Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. [https://doi.org/10.1016/j.ijrobp.2007.09.016 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18164847/ PubMed] [https://clinicaltrials.gov/study/NCT00033254 NCT00033254] |
[[Category:CNS carcinoma regimens]] | [[Category:CNS carcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] |
Latest revision as of 02:14, 31 July 2024
Section editor | |
---|---|
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
This page has regimens and guidelines that are not specific to any one type of cancer. For disease-specific regimens and guidelines, please go to the following pages:
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO
- 2022: Schiff et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline PubMed
ASCO/SNO/ASTRO
- 2021: Vogelbaum et al. Treatment for Brain Metastases PubMed
EANO/ESMO
- 2021: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours PubMed
- 2017: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours PubMed
ISRS
- 2022: Grishcuk et al. ISRS Technical Guidelines for Stereotactic Radiosurgery: Treatment of Small Brain Metastases (≤1 cm in Diameter) PubMed
- 2018: Chao et al. Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline PubMed
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.
All lines of therapy
Whole brain irradiation
WBRT: Whole-Brain Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Knisely et al. 2007 (RTOG 0118) | 2002-2004 | Phase 3 (C) | Thalidomide & WBRT | Did not meet primary endpoint of OS |
References
- RTOG 0118: Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00033254